Forty Seven

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
Flag link:
Forty Seven and AstraZenca Team up on NHL Triple-Combination Therapy
Forty Seven and AstraZenca Team up on NHL Triple-Combination Therapy
BioSpace
AstraZeneca
Forty Seven
clinical trials
diffuse large B-cell lymphoma
Flag link:
It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M
It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M
Endpoints
biotech
IPOs
Tricida
Translate Bio
Forty Seven
Neon Therapeutics
Aquestive Therapeutics
Flag link:
The Biotech IPO Rush Continues With Four More Coming Soon
The Biotech IPO Rush Continues With Four More Coming Soon
CP Wire
biotech
IPOs
Neon Therapeutics
Forty Seven
Translate Bio
Tricida
Flag link:
The Biotech IPO Rush Continues With Four More Coming Soon
biotech
IPOs
Neon Therapeutics
Forty Seven
Translate Bio
Tricida
Flag link:
Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven
Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven
Endpoints
Genentech
anti-PD-1 immunotherapy
Forty Seven
Flag link: